Vanguard Group Inc Cassava Sciences Inc Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,683,126 shares of SAVA stock, worth $79 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,683,126
Previous 2,356,480
13.86%
Holding current value
$79 Million
Previous $47.8 Million
30.7%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SAVA
# of Institutions
184Shares Held
13.3MCall Options Held
1.38MPut Options Held
2.04M-
Black Rock Inc. New York, NY3.22MShares$94.8 Million0.0% of portfolio
-
State Street Corp Boston, MA1.18MShares$34.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA967KShares$28.5 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA691KShares$20.3 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO582KShares$17.1 Million3.79% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $1.18B
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...